Nibentan in arresting acute atrial fibrillation: risk or benefit?
Chapurnykh, A.V.; Solov'ev, O.V.; Zavalin, A.V.; Pavlov, E.G.; Efremov, D.N.
Terapevticheskii Arkhiv 80(1): 41-45
2008
ISSN/ISBN: 0040-3660 PMID: 18326226 Document Number: 617379
Aim. To study efficacy and safety of using a domestic anti-arrhythmic drug nibentan for arresting acute atrial fibrillation.Material and methods. A total of 210 patients received nibentan in a dose 0.125 mg/kg dissolved in 20.0 ml of 0.9% sodium chloride solution by intravenous slow jet 3-min injection. In no response, the injection was repeated 20 min later. Nibentan injection was accompanied with continuous ECG monitoring, measurements of QT interval, arterial pressure. The criterion of efficacy was atrial fibrillation conversion into the sinus rhythm within 24 hours after injection of a total nibentan dose.Results. Nibentan in a dose 0.125 mg/kg demonstrated high efficacy (91.9%) and sufficient safety (incidence of polymorphic ventricular tachycardia 2.4%) including patients taking other antiarrhythmic drugs. A basic marker of an electrophysiological effect of nibentan on the myocardium is a dynamic change in the interval QT which may serve a predictor of sinus rhythm reestablishment (in QT >= 480 ms) and of a risk to develop proarrhythmogenic complications (in QT >= 640 ms).